Aug. 19 at 1:33 PM
$CHUC I’m bullish on CHUC because the story is improving on several fronts: Q2 revenue jumped 116% to
$3.8M, gross profit increased 130%, and gross margin improved to 29.4%. The company also has a potentially valuable portfolio of 678 PMTA applications, and the new IKE age-gating technology could strengthen those applications without requiring the company to start the process over. If Charlie’s can successfully incorporate that technology and generate strong compliance data, it could become a major catalyst. The risk is that the company is still losing money and has limited cash, so FDA progress and execution are critical. At around
$0.23, I see a favorable risk/reward setup, but the biggest potential upside comes from the PMTA/age-gating strategy actually translating into FDA approvals. 🤠